A high rate and fairly durable remission were achieved in a clinical trial involving subjects with relapsed or refractory T cell acute lymphoblastic leukemia (NCT04689659) with CD7-CAR T, while CD7-negative T cell expansion was observed in the subjects. The gene discussed is CD7; the disease is T-cell acute lymphoblastic leukemia.